Oncology Companion Diagnostic Market byTechnologyand Application- Global Industry Analysis & Forecast to 2027
Published On : September 2020 Pages : 154 Category: Pharma & Healthcare Report Code : HC0912912
Oncology Companion Diagnostic Market By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Other Technologies) and Application (Hospital, Pathology/Diagnostic Laboratory, Academic Medical Center)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Oncology Companion Diagnostic Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Oncology Companion Diagnostic is the invitro diagnostics and combination device products that assist patients and providers in screening, diagnosing, treating, and monitoring premalignant and malignant conditions.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Oncology Companion Diagnostic Marketand estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Agilent Technologies, Inc.
- Illumina, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- ARUP Laboratories
- Abbott
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Oncology Companion Diagnostic Market, ByTechnology, Estimates and Forecast, 2017-2027 ($Million)
o Polymerase Chain Reaction (PCR)
o Next-Generation Sequencing (NGS)
o Immunohistochemistry (IHC)
o In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
o Other Technologies
· Oncology Companion Diagnostic Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Hospital
o Pathology/Diagnostic Laboratory
o Academic Medical Center
· Oncology Companion Diagnostic Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Agilent Technologies, Inc.
o Illumina, Inc.
o QIAGEN N.V.
o Thermo Fisher Scientific, Inc.
o F. Hoffmann-La Roche Ltd.
o ARUP Laboratories
o Abbott
· Oncology Companion Diagnostic Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Oncology Companion Diagnostic Market , By Country
o U.S. Oncology Companion Diagnostic Market
o Canada Oncology Companion Diagnostic Market
o Mexico Oncology Companion Diagnostic Market
o Europe
§ Europe Oncology Companion Diagnostic Market , By Country
o UK Oncology Companion Diagnostic Market
o Germany Oncology Companion Diagnostic Market
o France Oncology Companion Diagnostic Market
o Russia Oncology Companion Diagnostic Market
o Italy Oncology Companion Diagnostic Market
o Rest of Europe Oncology Companion Diagnostic Market
o Asia-Pacific
§ Asia-Pacific Oncology Companion Diagnostic Market , By Country
o China Oncology Companion Diagnostic Market
o Japan Oncology Companion Diagnostic Market
o South Korea Oncology Companion Diagnostic Market
o India Oncology Companion Diagnostic Market
o Southeast Asia Oncology Companion Diagnostic Market
o Rest of Asia-Pacific Oncology Companion Diagnostic Market
o South America
§ South America Oncology Companion Diagnostic Market
o Brazil Oncology Companion Diagnostic Market
o Argentina Oncology Companion Diagnostic Market
o Columbia Oncology Companion Diagnostic Market
o Rest of South America Oncology Companion Diagnostic Market
o Middle East and Africa
§ Middle East and Africa Oncology Companion Diagnostic Market
o Saudi Arabia Oncology Companion Diagnostic Market
o UAE Oncology Companion Diagnostic Market
o Egypt Oncology Companion Diagnostic Market
o Nigeria Oncology Companion Diagnostic Market
o South Africa Oncology Companion Diagnostic Market
o TurkeyOncology Companion Diagnostic Market
o Rest of MEA Oncology Companion Diagnostic Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Oncology Companion Diagnostic Market, By Technology
5.1. Introduction
5.2. Global Oncology Companion Diagnostic Revenue and Market Share by Technology (2017-2021)
5.2.1. Global Oncology Companion Diagnostic Revenue and Revenue Share by Technology (2017-2021)
5.3. Polymerase Chain Reaction (PCR)
5.3.1. Global Polymerase Chain Reaction (PCR) Revenue and Growth Rate (2017-2021)
5.4. Next-Generation Sequencing (NGS)
5.4.1. Global Next-Generation Sequencing (NGS) Revenue and Growth Rate (2017-2021)
5.5. Immunohistochemistry (IHC)
5.5.1. Global Immunohistochemistry (IHC) Revenue and Growth Rate (2017-2021)
5.6. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
5.6.1. Global In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH) Revenue and Growth Rate (2017-2021)
5.7. Other Technologies
5.7.1. Global Other Technologies Revenue and Growth Rate (2017-2021)
6. Oncology Companion Diagnostic Market, By Applications
6.1. Introduction
6.2. Global Oncology Companion Diagnostic Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Oncology Companion Diagnostic Revenue and Revenue Share by Applications (2017-2021)
6.3. Hospital
6.3.1. Global Hospital Revenue and Growth Rate (2017-2021)
6.4. Pathology/Diagnostic Laboratory
6.4.1. Global Pathology/Diagnostic Laboratory Revenue and Growth Rate (2017-2021)
6.5. Academic Medical Center
6.5.1. Global Academic Medical Center Revenue and Growth Rate (2017-2021)
7. Oncology Companion Diagnostic Market, By Region
7.1. Introduction
7.2. Global Oncology Companion Diagnostic Revenue and Market Share by Regions
7.2.1. Global Oncology Companion Diagnostic Revenue by Regions (2017-2021)
7.3. North America Oncology Companion Diagnostic by Countries
7.3.1. North America Oncology Companion Diagnostic Revenue and Growth Rate (2017-2021)
7.3.2. North America Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Oncology Companion Diagnostic by Countries
7.4.1. Europe Oncology Companion Diagnostic Revenue and Growth Rate (2017-2021)
7.4.2. Europe Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Oncology Companion Diagnostic by Countries
7.5.1. Asia-Pacific Oncology Companion Diagnostic Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Oncology Companion Diagnostic by Countries
7.6.1. South America Oncology Companion Diagnostic Revenue and Growth Rate (2017-2021)
7.6.2. South America Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Oncology Companion Diagnostic by Countries
7.7.1. Middle East and Africa Oncology Companion Diagnostic Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Agilent Technologies, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Illumina, Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. QIAGEN N.V.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Thermo Fisher Scientific, Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. ARUP Laboratories
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Abbott
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
9. Oncology Companion Diagnostic Market Forecast (2022-2027)
9.1. Global Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Oncology Companion Diagnostic Market Forecast by Regions (2022-2027)
9.2.1. North America Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.1.1. United States Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.1.2. Canada Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.1.3. Mexico Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2. Europe Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2.1. Germany Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2.2. France Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2.3. UK Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2.4. Russia Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2.5. Italy Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3. Asia-Pacific Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3.1. China Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3.2. Japan Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3.3. Korea Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3.4. India Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.4. South America Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.4.1. Brazil Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.4.2. Argentina Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.4.3. Columbia Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.4.4. Rest of South America Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5. Middle East and Africa Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.3. Egypt Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.4. Nigeria Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.5. South Africa Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.6. Turkey Oncology Companion Diagnostic Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Oncology Companion Diagnostic Market Forecast (2022-2027)
9.3. Oncology Companion Diagnostic Market Forecast by Technology (2022-2027)
9.3.1. Oncology Companion Diagnostic Forecast by Technology (2022-2027)
9.3.2. Oncology Companion Diagnostic Market Share Forecast by Technology (2022-2027)
9.4. Oncology Companion Diagnostic Market Forecast by Applications (2022-2027)
9.4.1. Oncology Companion Diagnostic Forecast by Applications (2022-2027)
9.4.2. Oncology Companion Diagnostic Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Oncology Companion Diagnostic Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Oncology Companion Diagnostic Revenue and Revenue Share by Technology (2017-2019)
Figure Global Polymerase Chain Reaction (PCR) Revenue and Growth Rate (2017-2019)
Figure Global Next-Generation Sequencing (NGS) Revenue and Growth Rate (2017-2019)
Figure Global Immunohistochemistry (IHC) Revenue and Growth Rate (2017-2019)
Figure Global In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH) Revenue and Growth Rate (2017-2019)
Figure Global Other Technologies Revenue and Growth Rate (2017-2019)
Table Global Oncology Companion Diagnostic Revenue and Revenue Share by Applications (2017-2019)
Figure Global Hospital Revenue and Growth Rate (2017-2019)
Figure Global Pathology/Diagnostic Laboratory Revenue and Growth Rate (2017-2019)
Figure Global Academic Medical Center Revenue and Growth Rate (2017-2019)
Table Global Oncology Companion Diagnostic Revenue by Regions (2017-2019)
Figure North America Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure North America Oncology Companion Diagnostic Revenue and Growth Rate (2017-2019)
Figure North America Oncology Companion Diagnostic by Countries (2017-2019)
Figure North America Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2019)
Figure United States Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure United States Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Canada Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Mexico Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Europe Oncology Companion Diagnostic Revenue and Growth Rate (2017-2019)
Figure Europe Oncology Companion Diagnostic by Countries (2017-2019)
Figure Europe Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2019)
Figure Germany Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Germany Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure France Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure UK Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Russia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Italy Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Rest of Europe Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Asia-Pacific Oncology Companion Diagnostic Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Oncology Companion Diagnostic by Countries (2017-2019)
Figure Asia-Pacific Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2019)
Figure China Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure China Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Japan Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Korea Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure India Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Southeast Asia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure South America Oncology Companion Diagnostic Revenue and Growth Rate (2017-2019)
Figure South America Oncology Companion Diagnostic by Countries (2017-2019)
Figure South America Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Brazil Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Argentina Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Columbia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Rest of South America Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Middle East and Africa Oncology Companion Diagnostic Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Oncology Companion Diagnostic by Countries (2017-2019)
Figure Middle East and Africa Oncology Companion Diagnostic Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Saudi Arabia Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure United Arab Emirates Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Egypt Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Nigeria Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure South Africa Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Turkey Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oncology Companion Diagnostic Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2017-2019)
Table Agilent Technologies, Inc. Oncology Companion Diagnostic Financial Overview
Table Illumina, Inc. Oncology Companion Diagnostic Financial Overview
Table QIAGEN N.V. Oncology Companion Diagnostic Financial Overview
Table Thermo Fisher Scientific, Inc. Oncology Companion Diagnostic Financial Overview
Table F. Hoffmann-La Roche Ltd. Oncology Companion Diagnostic Financial Overview
Table ARUP Laboratories Oncology Companion Diagnostic Financial Overview
Table Abbott Oncology Companion Diagnostic Financial Overview
Figure Global Oncology Companion Diagnostic Revenue (Millions USD) and Growth Rate (2019-2027)
Table Oncology Companion Diagnostic Market Forecast by Regions (2019-2027)
Figure North America Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure United States Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Canada Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Mexico Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Europe Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Germany Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure France Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure UK Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Russia Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Italy Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Rest of Europe Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Asia-Pacific Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure China Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Japan Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Korea Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure India Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Southeast Asia Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure South America Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Brazil Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Argentina Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Columbia Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Rest of South America Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Middle East and Africa Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Saudi Arabia Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure United Arab Emirates Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Egypt Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Nigeria Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure South Africa Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Turkey Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Oncology Companion Diagnostic Market Forecast (2019-2027)
Figure Global Oncology Companion Diagnostic Forecast by Technology (2019-2027)
Figure Global Oncology Companion Diagnostic Market Share Forecast by Technology (2019-2027)
Figure Global Oncology Companion Diagnostic Forecast by Technology (2019-2027)
Figure Global Oncology Companion Diagnostic Forecast by Applications (2019-2027)
Figure Global Oncology Companion Diagnostic Market Share Forecast by Applications (2019-2027)
Figure Global Oncology Companion Diagnostic Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|